Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
Mar. 31, 2023	Mar. 31, 2022
Revenues	$ 105,984	$ 108,435
Cost of revenues	97,463	94,943
Gross profit	8,521	13,492
Operating expenses:
Research and development	8,966	10,470
Selling, general and administrative	28,700	27,494
Amortization of acquisition related intangibles	2,746	2,467
Change in fair value on contingent consideration	70	(5,850)
Restructuring	1,048	0
Total operating expenses	41,530	34,581
Operating loss	(33,009)	(21,089)
Interest income, net	252	75
China dissolution	(1,921)	0
Other expense, net	(148)	(28)
Loss before income tax expense (benefit)	(34,826)	(21,042)
Income tax expense (benefit)	215	(1,849)
Net loss	$ (35,041)	$ (19,193)
Net loss per common share
Basic (in dollars per share)	$ (1.26)	$ (0.71)
Diluted (in dollars per share)	$ (1.26)	$ (0.71)
Weighted average number of common shares outstanding
Basic (in shares)	27,848	27,203
Diluted (in shares)	27,848	27,203

The amount of expense recognized in the current period that reflects the allocation of capitalized costs associated with acquisition of business. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.

Name:	us-gaap_AmortizationOfAcquisitionCosts
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.